usa (2)

The latest version of this regular free round-up of US and Canadian regulation in the food industry, from legal firm DLA Piper, has been published on the Lexology blog platform.

13682610864?profile=RESIZE_400x

August's edition includes commentary on:

  • Plans to reorganise the USDA
  • New senior appointments at USDA and FDA
  • CFIA inspection frequency of Safe Food for Canadians (SFC) licensed premises
  • FDA releases new food toxicity screening tool
  • FDA food traceability compliance deadline extended to 2028
  • FDA-commissioned report: "Roadmap to Produce Safety: Summary Report of the Produce Safety Dialogue"
  • Saskatoon Farm foodborne illness outbreak linked to contaminated water.
  • FDA moves to reclassify a synthetic opioid derived from kratom as a controlled substance
  • FDA announces 2026 user fees for VQIP and TPP.
  • FDA proposes amending Standard of Identity for pasteurized orange juice
  • Canada-Australia beef trade reopens after 20-year ban.
  • Brazilian coffee companies redirect coffee sales to China in response to US tariffs
  • US tariffs may hurt US chocolate producers
  • Misleading “Made in Canada” branding prompts scrutiny of grocer compliance
  • Federal lawsuit targets Oregon’s Plastic Pollution and Recycling Modernization Act
  • CDC: Americans get more than half of their calories from ultra-processed foods.
  • IFIC report: consumer confidence in safety of the food supply is at a 13-year low
  • Avian flu update.
Read more…

4073070821?profile=RESIZE_710x

The US agencies have issued letters to seven companies, and removed online listings from others, whose products falsely claim to prevent or treat coronavirus.

The US Food and Drug Administration (FDA) and Federal Trade Commission (FTC) have issued warning letters to seven companies for selling fraudulent COVID-19 products that claim to treat or prevent the virus. At current there is no approved prevention or therapy for coronavirus.

According to the agencies, the products being sold are unapproved and pose a significant risk to patient health, as they may be unsafe for consumption and/or stop or delay patients getting necessary medical diagnoses and treatments.

The companies selling these products are violating federal law and may be subject to legal action, including but not limited to seizure or injunction, emphasise the organisations.

 

 

Read more…